|
Cannabis use
|
0.310 |
Biomarker
|
disease |
BEFREE |
Genes such as ELTD1 on chromosome 1, in addition to genes on chromosomes 4 (eg, GABRA2) and 6 (eg, CNR1), may be associated with the genetic risk for cannabis use disorders.
|
18519829 |
2008 |
|
Cannabis use
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Genes such as ELTD1 on chromosome 1, in addition to genes on chromosomes 4 (eg, GABRA2) and 6 (eg, CNR1), may be associated with the genetic risk for cannabis use disorders.
|
18519829 |
2008 |
|
Glioblastoma
|
0.220 |
Biomarker
|
disease |
BEFREE |
For example, ELTD1, a functionally validated glioblastoma oncogene located on 1p, was overexpressed.
|
29890994 |
2018 |
|
Glioblastoma
|
0.220 |
Biomarker
|
disease |
BEFREE |
MicroRNA-139-5p acts as a tumor suppressor by targeting ELTD1 and regulating cell cycle in glioblastoma multiforme.
|
26449464 |
2015 |
|
Glioblastoma
|
0.220 |
ModifyingMutation
|
disease |
RGD |
ELTD1, a potential new biomarker for gliomas.
|
23096411 |
2013 |
|
Adult Glioblastoma
|
0.210 |
Biomarker
|
disease |
BEFREE |
For example, ELTD1, a functionally validated glioblastoma oncogene located on 1p, was overexpressed.
|
29890994 |
2018 |
|
Adult Glioblastoma
|
0.210 |
ModifyingMutation
|
disease |
RGD |
ELTD1, a potential new biomarker for gliomas.
|
23096411 |
2013 |
|
Glioblastoma, IDH-Wildtype
|
0.200 |
ModifyingMutation
|
disease |
RGD |
ELTD1, a potential new biomarker for gliomas.
|
23096411 |
2013 |
|
Red Blood Cell Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
White Blood Cell Count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Eosinophil count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Adhesion G Protein-Coupled Receptor L4 (ADGRL4/ELTD1) is an endothelial cell adhesion G protein-coupled receptor (aGPCR) which regulates physiological and tumour angiogenesis, providing an attractive target for anti-cancer therapeutics.
|
31775252 |
2019 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
<b><i>Conclusion</i>:</b> The results of this study indicated that ELTD1 regulation of HCC progression is CAF-dependent, suggesting that ELTD1 function is regulated by its tumor microenvironment.
|
30026838 |
2018 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Untreated GL261 or G55 tumors were found to have significantly higher ELTD1 levels (IHC) compared with contralateral normal brain.
|
27416955 |
2017 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Importantly, ELTD1 silencing impairs endothelial sprouting and vessel formation in vitro and in vivo, drastically reducing tumor growth and greatly improving survival.
|
23871637 |
2013 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Significantly high (P < .001) in vivo levels of ELTD1 were additionally found in F98 tumors compared with normal brain tissue.
|
23096411 |
2013 |
|
Glioma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Taken together, our data provide a plausible mechanism for ELTD1-modulated glioma progression and suggest that ELTD1 may represent a potential therapeutic target in the prevention and therapy of glioma.
|
31554859 |
2019 |
|
Glioma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Tumor volume and survival data in this study show that antibodies against ELTD1 inhibit glioma growth just as effectively or even more so compared with other therapeutic targets studied, including anti-VEGF antibody therapy.
|
27416955 |
2017 |
|
Glioma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Validation was done with immunohistochemistry, which was used to detect levels of ELTD1 in human high-grade gliomas and rat F98 glioma tumors.
|
23096411 |
2013 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
The upregulation of ELTD1 ([epidermal growth factor (EGF), latrophilin and seven transmembrane domain-containing 1] on chromosome 1) in tumor cells has been reported in several types of cancer and correlates with poor cancer prognosis.
|
31554859 |
2019 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
The upregulation of ELTD1 ([epidermal growth factor (EGF), latrophilin and seven transmembrane domain-containing 1] on chromosome 1) in tumor cells has been reported in several types of cancer and correlates with poor cancer prognosis.
|
31554859 |
2019 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
<b><i>Results</i>:</b> Clinicopathologic correlations and <i>in vivo</i> models indicated ELTD1 as a tumor suppressor gene, whereas <i>in vitro</i> experiments suggested that ELTD1 could promote malignancy in HCC cell lines.
|
30026838 |
2018 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
<b><i>Results</i>:</b> Clinicopathologic correlations and <i>in vivo</i> models indicated ELTD1 as a tumor suppressor gene, whereas <i>in vitro</i> experiments suggested that ELTD1 could promote malignancy in HCC cell lines.
|
30026838 |
2018 |